For Physicians



To evaluate a survival benefit for custirsen in combination with first-line docetaxel treatment in approximately 1,000 patients with metastatic CRPC 

Trial Design: 

Randomized, open-label, two-arm trial of custirsen in ~1,000 chemotherapy-naive metastatic CRPC patients.

Arm A: 
Custirsen + Docetaxel + Prednisone
Arm B: 
Docetaxel + Prednisone
Primary Endpoint: 
Overall survival
Estimated Accrual Completion: 
Estimated Primary Endpoint Date: 
YE 2013
SPA completed with the FDA
Received Fast Track Designation
FDA stated that an application supported primarily by the results of SYNERGY alone would be acceptable for submission

External Link Pop Up Window

You are now exiting the OncoGenex Web site and entering a third party Web site.

OncoGenex does not review the information contained on the following Web site for content, accuracy or completeness. Use of and access to the information are subject to the terms, limitations and conditions set by the Web site producer. OncoGenex makes no claims about the accuracy or any other aspect of the information contained on this Web site, nor does OncoGenex necessarily endorse this Web site.

Stay on OncoGenex Continue